ARQT Stock Analysis: Arcutis Biotherapeutics | NASDAQ

Dermatology Treatments, Plaque Psoriasis, Atopic Dermatitis, Seborrheic Dermatitis

Total Rating 42

Safety 37

Buy Signal -0.36

Biotechnology
Sub-Industry Rotation: +3.7

Market Cap: 3.39B
Avg Turnover: 72.5M

Risk 3d forecast

Volatility51.7%

VaR 5^th Pctl8.24%

VaR vs Median-3.20%

Reward TTM

Sharpe Ratio0.51

Rel. Str. IBD76.6

Rel. Str. Peer Group54.3 pctl

Character TTM

Beta0.565

Beta Downside-0.165

Hurst Exponent0.518

Choppyness66.6%

Drawdowns 3y

Max DD42.22%

CAGR/Max DD3.34

CAGR/Mean DD9.19

EPS (Earnings per Share)

Last SUE: -1.54
Qual. Beats: -1

Revenue

Rev. CAGR: 105.52%
Rev. Trend: 97.9%

Last SUE: 0.28
Qual. Beats: 0

Warnings

P/E Ratio 122.7

Altman Z'' In Financial Distress Zone

Tailwinds

No distinct edge detected

Seasonality 6.8 years of data, until 10/2026

Jan -5.8% 5

Feb +10.6% 30

Mar -7.5% 0

Apr -1.9% 0

May -8.0% 30

Jun +3.5% 11

Jul +1.9% 0

Aug +0.1% 0

Sep +9.7% 0

Oct -8.6% 11

Nov +7.3% 0

Dec +2.6% 5

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: ARQT Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a U.S.-based biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California. The company specializes in developing and commercializing treatments for dermatological diseases, with a particular focus on inflammatory skin conditions. It was originally incorporated as Arcutis, Inc. before adopting its current name in October 2019.

The companys lead commercial product is ZORYVE, a topical roflumilast cream (a PDE4 inhibitor) approved for the treatment of plaque psoriasis and atopic dermatitis. Arcutis is also advancing a ZORYVE foam formulation for seborrheic dermatitis as well as scalp and body psoriasis, and developing ARQ-234, a fusion protein designed as a selective agonist of the CD200 receptor checkpoint.

As a GICS-classified Biotechnology company, Arcutis operates within a sector that typically depends on regulatory approvals, intellectual property protection, and the successful commercialization of pipeline assets to generate revenue. The companys strategy centers on reformulating and applying existing or validated mechanisms-such as PDE4 inhibition-through topical delivery, aiming to provide targeted therapies with reduced systemic exposure for chronic skin conditions.

Headlines to Watch Out For

ZORYVE sales accelerate in plaque psoriasis and atopic dermatitis
Competition from Dupixent and topical steroids pressures market share
Cash burn and potential capital raise weigh on shares

Piotroski VR-10 (Strict) 6.0

Net Income: 29.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 21.69 > 1.0
NWC/Revenue: 65.14% < 20% (prev 78.46%; Δ -13.33% < -1%)
CFO/TA 0.11 > 3% & CFO 60.0m > Net Income 29.9m
Net Debt (-139.3m) to EBITDA (39.8m): -3.50 < 3
Current Ratio: 2.92 > 1.5 & < 3
Outstanding Shares: last quarter (136.8m) vs 12m ago 2.97% < -2%
Gross Margin: 91.18% > 18% (prev 89.96%; Δ 1.22% > 0.5%)
Asset Turnover: 113.6% > 50% (prev 85.70%; Δ 27.92% > 0%)
Interest Coverage Ratio: 2.56 > 6 (EBIT TTM 35.2m / Interest Expense TTM 13.7m)

Altman Z'' -1.41

A: 0.63 (Total Current Assets 503.7m - Total Current Liabilities 172.4m) / Total Assets 524.4m
B: -2.15 (Retained Earnings -1.13b / Total Assets 524.4m)
C: 0.08 (EBIT TTM 35.2m / Avg Total Assets 447.7m)
D: 0.87 (Book Value of Equity 244.0m / Total Liabilities 280.5m)
Altman-Z'' = -1.41 = CCC

Beneish M -2.85

DSRI: 0.93 (Receivables 171.3m/115.1m, Revenue 508.7m/317.9m)
GMI: 0.99 (GM 89.96% / 91.18%)
AQI: 0.70 (AQ_t 0.03 / AQ_t-1 0.04)
SGI: 1.60 (Revenue 508.7m / 317.9m)
TATA: -0.06 (NI 29.9m - CFO 60.0m) / TA 524.4m)
Beneish M = -2.85 (Cap -4..+1) = A

What is the price of ARQT shares?

As of November 13, 2026, the stock is trading at USD 28.38 with a total of 2,456,746 shares traded. Over the past week, the price has changed by -16.65%, over one month by +8.24%, over three months by +8.20% and over the past year by +18.10%.

Current recommended Stop Loss: 23.60 (which is 16.8% or 2.6 ATR below the current price).

Is ARQT a buy, sell or hold?

Arcutis Biotherapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ARQT.

StrongBuy: 5
Buy: 2
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ARQT price?

Analysts Target Price	39.1	37.9%

Arcutis Biotherapeutics (ARQT) - Fundamental Data Overview as of 07 November 2026

Market Cap USD = 3.39b (3.39b USD * 1.0 USD.USD)
P/E Trailing = 122.7273
P/E Forward = 31.8471
P/S = 7.3143
P/B = 18.2544
Revenue TTM = 508.7m USD
EBIT TTM = 35.2m USD
EBITDA TTM = 39.8m USD
Long Term Debt = 108.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 6.95m USD (from shortTermDebt, last quarter)
Debt = 120.1m USD (corrected: LT Debt 108.0m + ST Debt 6.95m) + Leases 5.24m
Net Debt = -139.3m USD (calculated: Debt 120.1m - CCE 259.5m)
Enterprise Value = 3.25b USD (3.39b + Debt 120.1m - CCE 259.5m)
Interest Coverage Ratio = 2.56 (Ebit TTM 35.2m / Interest Expense TTM 13.7m)
EV/FCF = 54.51x (Enterprise Value 3.25b / FCF TTM 59.7m)
FCF Yield = 1.83% (FCF TTM 59.7m / Enterprise Value 3.25b)
FCF Margin = 11.74% (FCF TTM 59.7m / Revenue TTM 508.7m)
Net Margin = 5.88% (Net Income TTM 29.9m / Revenue TTM 508.7m)
Gross Margin = 91.18% ((Revenue TTM 508.7m - Cost of Revenue TTM 44.9m) / Revenue TTM)
Gross Margin QoQ = 91.34% (prev 91.58%)
Tobins Q-Ratio = 6.21 (Enterprise Value 3.25b / Total Assets 524.4m)
Interest Expense / Debt = 11.43% (Interest Expense 13.7m / Debt 120.1m)
Taxrate = 2.90% (894k / 30.8m)
NOPAT = 34.1m (EBIT 35.2m * (1 - 2.90%))
Current Ratio = 2.92 (Total Current Assets 503.7m / Total Current Liabilities 172.4m)
Debt / Equity = 0.49 (Debt 120.1m / totalStockholderEquity, last quarter 244.0m)
Debt / EBITDA = -3.50 (Net Debt -139.3m / EBITDA 39.8m)
Debt / FCF = -2.33 (Net Debt -139.3m / FCF TTM 59.7m)
Total Stockholder Equity = 210.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.68% (Net Income 29.9m / Total Assets 524.4m)
RoE = 14.18% (Net Income TTM 29.9m / Total Stockholder Equity 210.9m)
RoCE = 11.03% (EBIT 35.2m / Capital Employed (Equity 210.9m + L.T.Debt 108.0m))
RoIC = 10.24% (NOPAT 34.1m / Invested Capital 333.6m)
WACC = 7.66% (E(3.39b)/V(3.51b) * Re(7.54%) + D(120.1m)/V(3.51b) * Rd(11.43%) * (1-Tc(0.03)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.73 | Cagr: 4.67%
[DCF] Terminal Value 75.44% ; FCFF base≈59.7m ; Y1≈60.0m ; Y5≈63.5m
[DCF] Fair Price = 8.97 (EV 987.8m - Net Debt -139.3m = Equity 1.13b / Shares 125.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.54 | # QB: -1
Revenue Correlation: 97.92 | Revenue CAGR: 105.5% | SUE: 0.28 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.08 | Chg30d=-30.43% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=0.42 | Chg30d=-1.16% | Revisions=-25% | GrowthEPS=+426.9% | GrowthRev=+43.2%
EPS next Year (2027-12-31): EPS=1.34 | Chg30d=-1.60% | Revisions=+25% | GrowthEPS=+214.9% | GrowthRev=+29.2%
[Analyst] Revisions Ratio: +0% (up=1, down=1)